Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Dose Escalation and Dose in Combination With PD-1 Inhibitors Expansion Study to Assess the Safety and Efficacy of UNO - Ultra High Concentration Nitric Oxide Injection Into Unresectable Solid Cutaneous/Subcutaneous Primary or Metastatic Tumors

NCT05351502 is registered in ClinicalTrials.gov with Beyond Air Inc. as lead sponsor.

NCT NCT05351502
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05351502 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Dose Escalation and Dose in Combination With PD-1 Inhibitors Expansion Study to Assess the Safety and Efficacy of UNO - Ultra High Concentration Nitric Oxide Injection Into Unresectable Solid Cutaneous/Subcutaneous Primary or Metastatic Tumors
Lead sponsor
Beyond Air Inc.
Phase
Phase 1
Overall status
Terminated
Start date
August 14, 2022
Completion date
August 31, 2025
Enrollment
38 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

cancer